

## Multinuclear ( $^{19}\text{F}$ + $^1\text{H}$ ) MRI at 3T using an internal probe

Shashank Sathyanarayana Hegde<sup>1</sup>, Li Pan<sup>2</sup>, Guan Wang<sup>1,3</sup>, Martin Radvany<sup>1</sup>, Yingli Fu<sup>1</sup>, and Dara L Kraitchman<sup>1</sup>

<sup>1</sup>Radiology, Johns Hopkins University, Baltimore, Maryland, United States, <sup>2</sup>Siemens Healthcare, Baltimore, Maryland, United States, <sup>3</sup>Electrical and Computer Engineering, Johns Hopkins University, Maryland, United States

**Audience:** MR Interventionalists interested in monitoring therapeutic delivery of fluorinated drugs and cells.


**Purpose:** Fluorine ( $^{19}\text{F}$ ) MRI combined with anatomic proton ( $^1\text{H}$ ) MRI provides an effective method for tracking therapeutically labeled cells post-delivery<sup>1</sup> or fluorinated chemotherapeutics. Conventionally, surface and/or volume radiofrequency coils have been utilized for  $^{19}\text{F}/^1\text{H}$  MRI, but internal probes can yield higher local signal-to-noise ratios (SNR)<sup>2,3</sup>. Preliminary results from a 3T intravascular (IV) MRI probe designed for interchangeable  $^1\text{H}$  and  $^{19}\text{F}$  use have been previously reported<sup>4</sup>. Here, the signal-to-noise ratio (SNR) of the probe was studied,  $^{19}\text{F}$  MRI of a chemotherapeutic drug (5-fluorouracil: 5-FU,  $\text{C}_4\text{H}_3\text{FN}_2\text{O}_2$ , 50mg/mL) was investigated, and multinuclear MRI of prototype perfluorooctyl bromide (PFOB)-labeled microcapsules was performed in tissue samples *ex vivo* and in a rabbit thigh *in vivo*.

**Methods:** Experiments were conducted on a Siemens 3T (Tim Trio) system. A multinuclear IVMRI probe was designed using a 2.2mm outer-diameter 3T loopless antenna<sup>5</sup> with a 40mm resonant whip. The whip length was the same at  $^{19}\text{F}/^1\text{H}$  frequencies (123,116MHz)<sup>3</sup>, affording interchangeable operation (Fig. 1). The performance of the internal probe was compared with a conventional  $^{19}\text{F}$  surface coil by measuring the SNR in a test tube of trifluoro-acetic acid (TFA). The sensitivity of the IVMRI probe for 5-FU was performed by imaging serial dilutions, i.e., 25mg/mL (1:2) and 5mg/mL (1:10) dilutions. Microcapsules were produced using a modified alginate encapsulation method, with the addition of 12% (v/v) PFOB<sup>1</sup> and used for *ex vivo* and *in vivo* studies. *Ex vivo* studies were performed by inserting the IVMRI probe in the brachiocephalic trunk of an excised pig heart immersed in 3.5g/L saline, after injection of PFOB-impregnated microcapsules in the vessel adventitia. The IVMRI probe was inserted percutaneously in an anesthetized New Zealand White rabbit and the probe was alternately used for  $^1\text{H}$  and  $^{19}\text{F}$  MRI (Fig. 1) to detect percutaneously injected PFOB microcapsules. The proton and fluorine images were overlaid to form a composite image. MRI was followed by cone beam CT (CBCT) imaging (Artis Zee, Siemens) to confirm the deposition of the radiopaque microcapsules.


**Results:** The internal probe demonstrated increased SNR with respect to the surface coil for structures deeper than 2cm from the surface. Imaging of 10 fold dilutions of 5-FU was possible in two minutes, which were undetectable by a conventional surface coil. High-resolution (in-plane, up to 0.2mm  $^1\text{H}$ , 0.8mm  $^{19}\text{F}$ ) MRI of PFOB capsules was possible *ex vivo*<sup>4</sup>. *In vivo*, anatomical detail was provided by  $^1\text{H}$  MRI (Fig. 2a; 2D GRE;  $0.9 \times 0.7 \times 6 \text{ mm}^3$ ; TR/TE 7.8/3.69 ms; FA 20°). Using  $^{19}\text{F}$  MR spectroscopy, PFOB capsules could be detected followed by high resolution imaging (Figs. 2b, c.  $^{19}\text{F}$  MRS: STEAM; BW 20kHz; 40 avg; vector 512; amplitude 60 V.  $^{19}\text{F}$  MRI: 3D TruFISP; TR/TE= 12.5/6.2ms; FA = 11°; voxel =  $2 \times 2 \times 5 \text{ mm}^3$ ; 32 avg.). A composite overlay shows capsule injection with respect to the anatomy (Fig. 2d, magenta). The injection location was confirmed by CBCT (Fig. 2e, arrows) and by visual inspection *post mortem* (Fig. 2f).

**Conclusions:** A single 3T IV MRI detector was used for both  $^1\text{H}$  and  $^{19}\text{F}$  detection in phantoms, *ex vivo* and *in vivo*, using three  $^{19}\text{F}$  formulations: TFA, 5-FU, and PFOB-laden microcapsules. Such multi-nuclear IVMRI probes can be used to image/monitor  $^{19}\text{F}$ -labeled cells or drugs in deep structures *in vivo* that would be signal starved using surface coil imaging.

**References:** (1) Barnett BP, et al. Radiology. 2011;258(1):182-91 (2) Sathyanarayana S, et. al., JACC Card Im. 2010; 3:1158-1165. (3) El-Sharkawy AM et al. Med Phys 2008; 35:1995-2006. (4) Hegde S.S. et. al., Proc. ISMRM 22 (2014), 3698. (5) Ocali O, Atalar E. Magn. Reson. Med., 1997;37(1):112-118. Support: 2011-MSCRFII-0043, Siemens Corporation



**Figure 1:** Schematic of a  $^1\text{H}/^{19}\text{F}$  MRI switchable device.



**Figure 2:** (a) *In vivo*  $^1\text{H}$  MRI with internal probe *p* reveals muscle tissue. (b) An injection of PFOB capsules is detected by the probe via MR spectroscopy. (c)  $^{19}\text{F}$  IVMRI reveals the capsules. (d) A composite overlay of  $^1\text{H}$  and  $^{19}\text{F}$  MRI (magenta) reveals both anatomy and capsule location (arrows), as confirmed by (e) CT in the same location. Probe *p* is annotated. (f) A photograph of the tissue reveals the injected capsules. Scale bar :5mm.